Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BTBD9 antisense RNA 1 (BTBD9-AS1) is a long non-coding antisense RNA located on human chromosome 6, transcribed on the opposite strand relative to the BTBD9 gene[5][8]. As an lncRNA, BTBD9-AS1 does not code for proteins but is believed to have regulatory functions at the RNA level, potentially influencing the expression of the BTBD9 gene or other nearby genes through mechanisms such as transcriptional interference or chromatin remodeling[1][3][4][7]. While BTBD9 itself has been linked genetically to restless legs syndrome and regulation of neural and motor pathways, there is currently insufficient evidence to establish BTBD9-AS1 as a direct therapeutic target or to attribute specific disease roles to it. The study of lncRNAs like BTBD9-AS1 is an active field, and future research may clarify their functional and clinical significance[3][4][6]. Key points about BTBD9-AS1: - Canonical non-coding transcript, not a protein, enzyme, or receptor. - Acts primarily via gene regulation, especially in neural tissues. - No direct therapeutic interventions, drugs, or biomarker uses currently established. - Not a classical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BTBD9 antisense RNA 1 (BTBD9-AS1).